Today's Sequencing Capability

DNA sequencing is the important process of determining the sequence of nucleotides - DNA’s building blocks. One of the highly promising uses of DNA sequencing is early diagnostics even before the disease emerges, among several other important applications. The challenge facing the sequencing industry today is high prices, limited read lengths and low accuracy. Due to the high error rates and and high costs, sequencing still has limited applications and it far short of its potential. The Industry’s current goal to achieve $1,000 per genome is not even close to what is actually needed.

In every single one of our cells, during cell division, DNA polymerase duplicates our DNA by making a complementary strand using a single strand of DNA molecule as a template. 

It essentially «sequences» DNA while attaching complementary nucleotides(building blocks of DNA) to the template strand.

While doing that it makes one error per hundred million base pairs that is 0.000001% (It is more than 10 million times better than the best sequencing technology out there!)

DNA polymerase is the ultimate sequencer. 

Sarmal is developing a proprietary, revolutionary single molecule DNA sequencing technology - FLASH™ (FLuorescene Activation by Serial Hybridization) Sequencing, a paradigm shift in sequencing methods. The breakthrough technology is based on monitoring DNA replication in real-time. During FLASH™ Sequencing, each fluorescently tagged nucleotide generates a unique signal as a “flash” during natural DNA synthesis that is then converted to a digital signal with a very low error rate.  The Company plans to commercialize its FLASH™ Sequencing technology into DNA sequencing devices, consumables, and kits.

FLASH™ Sequencing is the next generation of sequencing technology for the first time can achieve essentially unlimited read-lengths without sacrificing accuracy. DNA replication occurs in natural conditions that makes error rates close to that can be seen in nature. And, this new method is projected to reduce cost for whole genome sequencing down from thousands of dollars to well under $100 dollars with unmatched specificity and sensitivity. 

Sarmal aims to achieve whole genome sequencing for under $100 per genome

with error rates close to natural polymerase (0.000001%)